Cosopt is a prescription eye-drop solution for adults with ocular hypertension or open-angle glaucoma. It combines dorzolamide hydrochloride with timolol maleate to lower eye pressure by reducing aqueous humour production through complementary mechanisms.
Cosopt is a prescription eye-drop solution containing dorzolamide hydrochloride and timolol maleate. It is used for adults with ocular hypertension or open-angle glaucoma when lowering eye pressure is clinically necessary. The two active ingredients reduce aqueous humour production through complementary mechanisms.
Cosopt is a sterile ophthalmic solution containing dorzolamide hydrochloride and timolol maleate. The dose is stated on the pack; follow the leaflet. The combination is also described pharmacologically as dorzolamide–timolol.
Dorzolamide belongs to the topical carbonic anhydrase inhibitor class. Timolol is a non-selective beta-adrenergic receptor blocker. Together, they reduce the formation of aqueous humour, the fluid circulating within the front part of the eye. Lower fluid production can reduce intraocular pressure and limit pressure-related stress on the optic nerve [1].
Dorzolamide hydrochloride inhibits carbonic anhydrase II in the ciliary processes of the eye. This enzyme contributes to bicarbonate formation and fluid secretion. Inhibition reduces the movement of sodium and fluid into the posterior chamber, lowering aqueous humour production.
The dorzolamide component acts locally after installation, though some systemic absorption can occur through the conjunctiva and nasolacrimal drainage system. A bitter taste after instillation is possible because some of the drop may reach the throat through the tear duct.
Timolol maleate blocks beta-adrenergic stimulation in the ciliary body. This decreases aqueous humour formation without directly constricting the pupil or changing accommodation in the way some older glaucoma treatments can.
Timolol can enter the systemic circulation. Its beta-blocking action may affect the heart and airways, which explains the need for caution in people with asthma, chronic obstructive pulmonary disease, slow heart rate, or certain conduction disorders.
The usual adult dose is one drop of Cosopt in the affected eye or eyes twice daily. If another topical glaucoma medicine is being replaced, the previous treatment is generally stopped and Cosopt is started according to the prescriber’s schedule.
One drop is enough for the eye. Adding extra drops does not improve pressure control and increases the amount that can drain into the nose. Contact-lens wearers should remove lenses before applying the solution and follow the prescriber’s instructions about when to replace them.
If a dose is missed, it should be used when remembered unless the next scheduled dose is close. In that situation, the missed dose is skipped. Two doses should not be applied together.
Cosopt is supplied here as eye drops in a bottle containing 5 ml. The solution should not be transferred to another container. Storage should follow the product’s approved instructions, and excessive heat or freezing should be avoided.
Dorzolamide hydrochloride inhibits carbonic anhydrase II in the ciliary processes of the eye, reducing bicarbonate formation and fluid secretion. This decreases the movement of sodium and fluid into the posterior chamber and lowers aqueous humour production.
Timolol maleate blocks beta-adrenergic stimulation in the ciliary body. This decreases aqueous humour formation without directly constricting the pupil or changing accommodation.
Cosopt is used to lower raised intraocular pressure in adults with open-angle glaucoma or ocular hypertension. It is commonly considered when a topical beta-blocker alone does not reduce pressure sufficiently, or when a patient is already receiving both mechanisms separately and a combination drop is clinically suitable.
Glaucoma can damage the optic nerve gradually, often without pain or early changes in vision. Ocular hypertension means that pressure is elevated without established optic-nerve damage, although some people with ocular hypertension later develop glaucoma. The Ocular Hypertension Treatment Study helped establish the importance of assessing individual risk rather than treating pressure as an isolated number [2].
| Clinical situation | Role of Cosopt | Monitoring focus |
|---|---|---|
| Open-angle glaucoma | Lowers aqueous humour production through two mechanisms | Intraocular pressure, optic nerve, visual field |
| Ocular hypertension | May reduce pressure when treatment is indicated | Pressure trend and glaucoma risk factors |
| Inadequate response to one topical agent | Provides combined carbonic anhydrase inhibition and beta-blockade | Response, tolerability, pulse and respiratory symptoms |
Cosopt does not restore damaged optic-nerve fibres. Its purpose is pressure control, which may help slow further damage when the treatment target is appropriate. The target pressure differs between patients because it depends on baseline pressure, optic-nerve appearance, visual-field findings, corneal thickness, age, and the stage of glaucoma.
A patient with ocular hypertension may receive a different pressure target from someone with established visual-field loss. Ophthalmology follow-up remains necessary even when vision feels unchanged.
Cosopt combines two active mechanisms in one bottle. Other glaucoma strategies may use a single mechanism, a different combination, laser treatment, or surgery depending on the pressure target and optic-nerve risk.
| Treatment approach | Main pressure-lowering principle | Practical limitation |
|---|---|---|
| Cosopt | Reduces aqueous humour production through carbonic anhydrase inhibition and beta-blockade | Timolol may affect breathing or heart rate |
| Prostaglandin-type eye drops | Increase uveoscleral outflow | May cause eyelash, iris, or periocular changes |
| Topical carbonic anhydrase inhibitor alone | Reduces aqueous humour formation | May provide less pressure reduction than dual therapy |
| Laser or surgery | Improves fluid outflow or bypasses resistance | Requires an ophthalmic procedure and follow-up |
The choice depends on the patient’s diagnosis, target pressure, ocular surface, cardiovascular history, respiratory history, previous treatment response, and ability to use drops consistently. Cosopt can reduce the number of bottles required when both components are appropriate, though a combination bottle does not remove the need for regular review.
Patients with asthma or significant bradycardia may require a different pressure-lowering strategy because of the timolol component. People with marked ocular-surface irritation may also need an adjustment in formulation or treatment plan.
Cosopt is not suitable for everyone. It should not be used in people with:
Important interactions include oral or intravenous beta-blockers, calcium-channel blockers, antiarrhythmics, cardiac glycosides, clonidine, and medicines that lower blood pressure. Combining these treatments can increase the risk of bradycardia, hypotension, conduction problems, or heart failure. Carbonic anhydrase inhibitors taken by mouth may also increase the risk of metabolic or electrolyte-related adverse effects.
Cosopt may affect the response to anaesthetic medicines. Patients scheduled for surgery should ensure that the anaesthetist knows they use ophthalmic timolol.
This may not be suitable for you if you have asthma, serious breathing problems, a very slow pulse, certain heart-block conditions, heart failure, or a serious allergy to dorzolamide, timolol, sulfonamides, or similar eye drops. Tell your prescriber if you have diabetes, thyroid disease, circulation problems, low blood pressure, kidney or liver disease, myasthenia gravis, or previous eye surgery. Seek immediate medical help for facial swelling, a blistering rash, fever, difficulty breathing, fainting, or a very slow heartbeat.
Cosopt can cause local eye reactions and systemic beta-blocker effects. The product information describes ocular irritation, burning or stinging, blurred vision, tearing, conjunctival changes, superficial punctate keratitis, and eyelid or corneal symptoms among possible reactions. The exact experience varies between patients.
| Reaction pattern | Possible symptoms | Clinical significance |
|---|---|---|
| Local ocular effects | Stinging, burning, itching, tearing, blurred vision | Often occurs around instillation; persistent pain or visual change needs assessment |
| Ocular-surface effects | Dryness, conjunctival redness, superficial punctate keratitis | May affect comfort and adherence |
| Systemic beta-blocker effects | Slow pulse, dizziness, fatigue, wheezing, shortness of breath | Requires prompt clinical attention, especially with respiratory or cardiac disease |
Dorzolamide may cause a bitter taste, nausea, headache, or fatigue. Timolol can produce systemic beta-blockade despite being applied to the eye. Possible effects include bradycardia, hypotension, faintness, worsening heart failure, bronchospasm, sleep disturbance, or cold hands and feet.
Rare but serious reactions include severe breathing difficulty, fainting, marked slowing of the heartbeat, swelling of the face or throat, widespread rash, or signs of a severe allergic reaction. Sudden eye pain, a rapid decline in vision, pronounced light sensitivity, or a new visual field defect also requires urgent ophthalmic assessment.
Some patients notice short-lived blurred vision immediately after the drop. Driving or operating machinery should wait until vision is clear. The bottle should not be shared, even when another person has similar eye-pressure treatment.
A useful detail is that punctal occlusion changes exposure. Pressing the inner corner of the eye after administration can reduce nasal absorption and may lower the chance of systemic beta-blocker symptoms.
Several practical mistakes can reduce the amount of medicine reaching the eye or increase adverse effects:
A surprisingly common error is confusing a drop that landed on the eyelid with a drop that entered the conjunctival sac. Repeating the dose immediately can increase exposure. If uncertain, patients should follow the prescriber’s missed-dose instructions rather than repeatedly adding drops.
Another mistake is judging treatment by comfort alone. Glaucoma can progress without pain, and a comfortable eye does not prove that pressure is controlled. The relevant evidence comes from ophthalmic measurements and optic-nerve assessment.
In clinical practice, ophthalmologists usually set a pressure target rather than treating a single reading in isolation. The target may be lower when the optic nerve already shows damage, when visual-field loss is progressing, or when other risk factors are present.
A doctor would usually explain that Cosopt controls pressure only while it is used consistently. Missing occasional doses can reduce control, while stopping treatment abruptly without a replacement plan may allow pressure to rise. The treatment response is assessed through measurements over time, not by whether the drops produce an immediate sensation.
The World Health Organization recognises glaucoma as a major cause of irreversible vision loss, which makes pressure monitoring and treatment adherence central to long-term care [3]. Cosopt may be useful when dual pharmacology is needed, but intolerance to timolol can make another approach more appropriate.
Cosopt is used to lower elevated intraocular pressure in open-angle glaucoma and ocular hypertension. The combination contains dorzolamide hydrochloride and timolol maleate, which reduce aqueous humour production through separate mechanisms. South African ophthalmic practice under SAHPRA oversight uses pressure measurements and optic-nerve findings to guide treatment decisions in 2026.
Pressure reduction begins after topical administration, but the clinically useful response is assessed through follow-up measurements rather than symptoms. The time needed to reach an individual target varies with baseline pressure, disease stage, and other eye treatments. The Ocular Hypertension Treatment Study provides important background for risk-based pressure management, with findings published in 2002.
Yes. Timolol can be absorbed systemically and may cause bronchospasm or worsen respiratory disease. People with asthma, a history of bronchospasm, or severe chronic obstructive pulmonary disease should not use Cosopt unless a specialist has established an appropriate alternative plan. The European Medicines Agency product information identifies these respiratory contraindications in its ophthalmic beta-blocker guidance from 2019.
Cosopt can be prescribed alongside other ophthalmic medicines, but the drops should usually be separated by at least 10 minutes. The interval reduces washout and helps each medicine remain on the ocular surface. Ophthalmology treatment protocols described by the American Academy of Ophthalmology use separated administration for multiple topical therapies, as stated in 2020 guidance.
A missed dose should be used when remembered unless the next scheduled dose is close. The missed dose should then be skipped, rather than doubled. This approach is consistent with the dosing principles described in the FDA prescribing information for dorzolamide hydrochloride and timolol maleate, published in 2020.
Pregnancy and breastfeeding require an individual assessment because dorzolamide and timolol can produce systemic exposure after eye-drop administration. The prescriber considers the severity of the eye condition, alternative treatments, and potential infant exposure. EMA medicine-safety principles published in 2019 require these factors to be reviewed before treatment is continued or started.
The inner corner overlies the beginning of the nasolacrimal drainage system. Gentle pressure can reduce the amount of Cosopt reaching the nose and throat, which may decrease systemic absorption of timolol. Guidance from the National Institute for Health and Care Excellence, published in 2022, includes punctal occlusion as a practical technique for topical glaucoma medicines.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
The first few applications stung for less than a minute. I found the inner-corner pressure technique easier after my sister showed me how to keep my head still. My follow-up pressure was lower, although I still needed regular field testing.
The drops helped my pressure, but I noticed a bitter taste and occasional tiredness. The taste improved when I kept my eyes closed and pressed near the nose. My ophthalmologist checked my pulse before continuing.
The treatment was convenient because Cosopt combined two medicines. I initially used both drops one after another, which caused more blur. Leaving a gap made the routine easier.
I did not notice a change in vision, so I assumed the medicine was unnecessary. The pressure reading at review showed why the drops had been prescribed. The main difficulty was remembering the evening dose.
